Chemotherapy for newly diagnosed and relapsed advanced ovarian cancer.
To review chemotherapy options for patients with newly diagnosed or relapsed advanced ovarian cancer. Published literature. Primary chemotherapy for newly diagnosed, advanced ovarian cancer consisting of a platinum compound and a taxane is commonly associated with myelosuppression, nausea/vomiting, alopecia, and sensory/motor neuropathy. For recurrent disease, numerous chemotherapy agents are effective, including rechallenging the patient with a platinum and/or a taxane or using newer agents such as pegylated liposomal doxorubicin, topotecan, and gemcitabine. In platinum-resistant disease, selection is based mainly on the toxicity profile, because palliation and quality of life are important. Oncology nurses play a valuable role in ovarian cancer care by proactively meeting patient information needs.